SHANGHAI, China, Feb. 26 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) (“China-Biotics”, “the Company”), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has joined the International Probiotics Association (“IPA”) as an official member.
“We are very excited to join the International Probiotics Association, the premier professional organization for probiotics producers,” said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. “With more than 10 years of experience in the industry, we continue to leverage our technical strength and find new and diverse applications for probiotics. We are committed to becoming the dominant supplier of naturally occurring probiotic bacteria in China, and our inclusion in the IPA is just the latest example of our commitment.”
“China-Biotics is the first diversified probiotics manufacturer from mainland China, to join the IPA. Having such an important player as one of our industry members expands the network of IPA greatly and gives the Chinese industry greater representation in the organization, which is composed of most of the probiotics industry’s world leaders,” said Ioannis Misopoulos, Executive Director of the IPA. “We look forward to sharing expertise and experience among our global leadership.”
About International Probiotics Association
IPA is an international organization equally split between industry and academia. Its goal is to provide a unique forum for the exchange of research and latest breakthroughs in probiotic technology and new product development. Additionally, the IPA works with government bodies and the industry to assist in establishing scientific standards for probiotic supplements, probiotic pharmaceutical products and functional foods. It has more than 30 member companies.
For more information, please visit http://www.internationalprobiotics.org .
About China-Biotics, Inc.
Headquartered in Shanghai, China-Biotics, Inc. (“China-Biotics”, “the Company”) was founded in 1999 and is one of China’s largest suppliers of probiotics. Probiotics are beneficial live bacteria used as dietary supplements and food additives to improve intestinal health and digestion. The Company’s product portfolio contains live microbials made with proprietary technology. Currently, these products are sold over-the-counter under the “Shining” brand through large distributors to more than 1,000 pharmacies and 100 supermarkets in Shanghai, Jiangsu and Zhejiang. Shining is one of the most recognized brands in Shanghai. China-Biotics plans to expand its retail sales to other major cities in China and will launch 300 Shining brand logistic centers in these cities during the next two years. The Company’s flagship product, “Shining Essence”, has been a profit driver since its launch in April 2001. There is a significant demand for probiotics for use in the bulk additive market, which is currently met by imports. China-Biotics is building a new plant which will increase its production capacity manifolds to capture this market. For more information, please visit http://www.chn-biotics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company’s ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
CCG Elite Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
